24/10/2026 19:22
|
Medical, Health & Aged Care
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer
Brain-penetrant PRMT5...